Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CHEK NASDAQ:DRCT NASDAQ:PBYI NASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHEKCheck-Cap$0.74+12.6%$0.71$0.56▼$3.04$4.31M0.19337,298 shs150,824 shsDRCTDirect Digital$0.40-3.3%$0.50$0.38▼$6.59$8.90M6.011.05 million shs795,800 shsPBYIPuma Biotechnology$4.54-3.6%$4.13$2.32▼$6.07$228.68M1.38483,665 shs129,626 shsSLGLSol-Gel Technologies$24.95-3.8%$15.03$4.01▼$30.00$68.15M1.2623,774 shs2,643 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHEKCheck-Cap-3.88%-6.68%-2.45%-19.12%-65.05%DRCTDirect Digital-3.65%-10.82%-3.62%-24.97%-85.05%PBYIPuma Biotechnology+3.29%-7.83%+27.64%+33.05%+103.02%SLGLSol-Gel Technologies-5.88%+10.91%+62.16%+274.71%+347.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHEKCheck-Cap$0.74+12.6%$0.71$0.56▼$3.04$4.31M0.19337,298 shs150,824 shsDRCTDirect Digital$0.40-3.3%$0.50$0.38▼$6.59$8.90M6.011.05 million shs795,800 shsPBYIPuma Biotechnology$4.54-3.6%$4.13$2.32▼$6.07$228.68M1.38483,665 shs129,626 shsSLGLSol-Gel Technologies$24.95-3.8%$15.03$4.01▼$30.00$68.15M1.2623,774 shs2,643 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHEKCheck-Cap-3.88%-6.68%-2.45%-19.12%-65.05%DRCTDirect Digital-3.65%-10.82%-3.62%-24.97%-85.05%PBYIPuma Biotechnology+3.29%-7.83%+27.64%+33.05%+103.02%SLGLSol-Gel Technologies-5.88%+10.91%+62.16%+274.71%+347.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHEKCheck-Cap 0.00N/AN/AN/ADRCTDirect Digital 2.50Moderate Buy$6.001,365.20% UpsidePBYIPuma Biotechnology 3.00Buy$7.0048.62% UpsideSLGLSol-Gel Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SLGL, CHEK, DRCT, and PBYI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025DRCTDirect DigitalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHEKCheck-CapN/AN/AN/AN/A($0.25) per shareN/ADRCTDirect Digital$62.29M0.15N/AN/A($1.21) per share-0.34PBYIPuma Biotechnology$230.50M1.03$0.88 per share5.35$1.88 per share2.51SLGLSol-Gel Technologies$11.54M6.27N/AN/A$10.36 per share2.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHEKCheck-Cap-$25.15M-$3.00N/A∞N/AN/AN/AN/AN/ADRCTDirect Digital-$6.24M-$1.83N/AN/AN/A-25.99%N/A-36.29%11/11/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.984.8112.39N/A20.38%53.15%23.51%11/6/2025 (Estimated)SLGLSol-Gel Technologies-$10.58M-$1.23N/AN/AN/A-14.25%-11.80%-9.39%11/14/2025 (Estimated)Latest SLGL, CHEK, DRCT, and PBYI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025SLGLSol-Gel Technologies-$0.67$4.17+$4.84$4.17$2.86 million$17.26 million8/5/2025Q2 2025DRCTDirect Digital-$0.96-$0.23+$0.73-$0.23$11.84 million$10.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHEKCheck-CapN/AN/AN/AN/AN/ADRCTDirect DigitalN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHEKCheck-CapN/A0.150.15DRCTDirect DigitalN/A0.490.49PBYIPuma Biotechnology0.101.731.62SLGLSol-Gel TechnologiesN/A7.327.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHEKCheck-Cap1.07%DRCTDirect Digital4.02%PBYIPuma Biotechnology61.29%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipCHEKCheck-Cap0.48%DRCTDirect Digital62.82%PBYIPuma Biotechnology23.30%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHEKCheck-Cap805.85 million5.82 millionNot OptionableDRCTDirect Digital6022.52 million8.37 millionNot OptionablePBYIPuma Biotechnology20050.37 million38.64 millionOptionableSLGLSol-Gel Technologies502.79 million933,000OptionableSLGL, CHEK, DRCT, and PBYI HeadlinesRecent News About These CompaniesSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 36.6% in AugustSeptember 8 at 7:41 AM | marketbeat.comSol-Gel Announces Health Canada Approval of EPSOLAY®September 4, 2025 | finance.yahoo.comSol-Gel Technologies announces Health Canada approval of EPSOLAYSeptember 4, 2025 | msn.comSol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 240% return over the last yearSeptember 4, 2025 | finance.yahoo.comSol Gel Technologies trading halted, volatility trading pauseAugust 22, 2025 | msn.comSol-Gel Stock Delivers Over 150% Gain - Can The Upcoming Q4 Clinical Data Readout Sustain The Rally? August 21, 2025 | rttnews.comSol-Gel Technologies Reports Strong Q2 2025 ResultsAugust 20, 2025 | msn.comSol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 15, 2025 | globenewswire.comSol-Gel Technologies Ltd. (SLGL) Stock Price Today - WSJJuly 25, 2025 | wsj.comSol-Gel Technologies Ltd. (SLGL) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comSLGL Sol-Gel Technologies Ltd. - Seeking AlphaJune 26, 2025 | seekingalpha.comSol-Gel Technologies LtdJune 21, 2025 | morningstar.comMSol Gel Tech Stock Price HistoryJune 1, 2025 | investing.comSol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | finanznachrichten.deSol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays PessimisticMay 23, 2025 | msn.comSol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D ExpensesMay 23, 2025 | quiverquant.comQSol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | globenewswire.comInsider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of SharesMay 3, 2025 | uk.finance.yahoo.comThis Sol-Gel Technologies Insider Increased Their Holding In The Last YearMay 2, 2025 | finance.yahoo.comSol-Gel Announces Reverse Share SplitMay 1, 2025 | globenewswire.comSol-Gel, Mayne Pharma enter product purchase agreementApril 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLGL, CHEK, DRCT, and PBYI Company DescriptionsCheck-Cap NASDAQ:CHEK$0.74 +0.08 (+12.62%) As of 12:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.Direct Digital NASDAQ:DRCT$0.40 -0.01 (-3.30%) As of 12:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Direct Digital Holdings, Inc. operates as an end-to-end full-service programmatic advertising platform. The company's platform primarily focuses on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy- and sell-side of the digital advertising ecosystem. It serves various industry verticals, such as travel, healthcare, education, financial services, consumer products, and other sectors with a focus on small and mid-sized businesses. The company was founded in 2018 and is headquartered in Houston, Texas.Puma Biotechnology NASDAQ:PBYI$4.54 -0.17 (-3.61%) As of 12:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Sol-Gel Technologies NASDAQ:SLGL$24.95 -0.98 (-3.78%) As of 12:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market The Quiet Before the Catalyst: Vertical Aerospace's Next Move Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
